Search
Rongchang Biopharmaceuticals Receives Orphan Drug Designation for Tacitupimab from the European Commission
1 week ago /
Read about 0 minute
Author：小编
Rongchang Biopharmaceuticals has proudly announced that its groundbreaking product, Tacitupimab, has been bestowed with Orphan Drug Designation by the European Commission for the treatment of myasthenia gravis. Tacitupimab stands as the world's first innovative BLyS/APRIL dual-target fusion protein drug, effectively curtailing the production of pathogenic autoantibodies by strategically blocking signaling pathways. This prestigious designation will significantly bolster the development of Tacitupimab within the European Union, offering an array of policy supports such as R&D assistance, fee exemptions, and a coveted 10-year market exclusivity period, among other valuable benefits.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
